Ionis Pharmaceuticals, Inc. Share Price

Equities

IONS

US4622221004

Biotechnology & Medical Research

Market Closed - Nasdaq 21:00:00 15/05/2024 BST 5-day change 1st Jan Change
39.21 USD +2.46% Intraday chart for Ionis Pharmaceuticals, Inc. -2.37% -22.49%
Sales 2024 * 599M 47.32B Sales 2025 * 767M 60.59B Capitalization 5.72B 452B
Net income 2024 * -575M -45.44B Net income 2025 * -518M -40.93B EV / Sales 2024 * 8.6 x
Net cash position 2024 * 567M 44.81B Net Debt 2025 * 318M 25.13B EV / Sales 2025 * 7.87 x
P/E ratio 2024 *
-10.3 x
P/E ratio 2025 *
-11.8 x
Employees 927
Yield 2024 *
-
Yield 2025 *
-
Free-Float 99.13%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.20%
1 week-2.37%
Current month-4.97%
1 month-5.63%
3 months-13.41%
6 months-21.22%
Current year-22.49%
More quotes
1 week
38.26
Extreme 38.26
39.78
1 month
38.26
Extreme 38.26
43.76
Current year
38.26
Extreme 38.26
54.44
1 year
35.44
Extreme 35.4401
54.44
3 years
25.04
Extreme 25.04
54.44
5 years
25.04
Extreme 25.04
73.09
10 years
19.59
Extreme 19.5927
86.58
More quotes
Managers TitleAgeSince
Founder 58 30/06/12
Founder 62 09/01/89
Director of Finance/CFO 62 30/04/00
Members of the board TitleAgeSince
Chairman 72 02/02/14
Founder 62 09/01/89
Director/Board Member 70 09/06/19
More insiders
Date Price Change Volume
15/05/24 39.21 +2.46% 1,256,373
14/05/24 38.27 -1.37% 983,112
13/05/24 38.8 -0.72% 1,045,266
10/05/24 39.08 -0.99% 895,065
09/05/24 39.47 -1.72% 1,300,598

Delayed Quote Nasdaq, May 15, 2024 at 09:00 pm

More quotes
Ionis Pharmaceuticals, Inc. is engaged in ribonucleic acid (RNA)-targeted therapeutics. The Company has five marketed medicines and a pipeline in neurology, cardiology, and other areas of high patient need. It has nine medicines in Phase III development and multiple additional medicines in early and mid-stage development. The Company’s products include SPINRAZA, QALSODY, WAINUA, TEGSEDI and WAYLIVRA. SPINRAZA is used for the treatment of patients with spinal muscular atrophy (SMA), a progressive, debilitating and often fatal genetic disease. QALSODY is an antisense medicine that is used for the treatment of adult patients with superoxide dismutase 1 amyotrophic lateral sclerosis (SOD1-ALS), a rare, neurodegenerative disorder that causes progressive loss of motor neurons leading to death. WAINUA is a self-administered subcutaneous LIgand-Conjugated Antisense (LICA) medicine used for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis (ATTRv-PN).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
39.21 USD
Average target price
57.95 USD
Spread / Average Target
+47.79%
Consensus